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Abstract
Introduction
Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. Howev-
er, side effects including hyperbilirubinemia, dyslipidemia, nephrolithiasis and cholelithiasis
have been reported in the medium and long term. Unboosted ATV may be selected for
some patients because it has fewer gastrointestinal adverse effects, less hyperbilirubinemia
and less impact on lipid profiles.
Methods
We investigated the distribution of ATV plasma trough concentrations according to drug
dosage and the potential relationship between ATV plasma trough concentrations and
drug-related adverse events in a consecutive series of 240 HIV-infected patients treated
with ATV/r 300/100 mg (68%) or ATV 400 mg (32%).
Results
43.9% of patients treated with ATV/r 300/100 mg had ATV concentrations exceeding the
upper therapeutic threshold. A significant and direct association has been observed between
the severity of hyperbilirubinemia and ATV plasma trough concentrations (ATV concentra-
tions: 271 [77–555], 548 [206–902], 793 [440–1164], 768 [494–1527] and 1491 [1122–1798]
ng/mL in patients with grade 0, 1, 2, 3 and 4 hyperbilirubinemia, respectively). In an explorato-
ry analysis we found that patients with dyslipidemia or nephrolitiasis had ATV concentrations
significantly higher (582 [266–1148], and 1098 [631–1238] ng/mL, respectively) (p<0.001), as
compared with patients with no ATV-related complications (218 [77–541] ng/mL).
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Conclusions
A significant proportion of patients treated with the conventional dosage of ATV (300/100)
had plasma concentrations exceeding the upper therapeutic threshold. These patients that
are at high risk to experience ATV-related complications may benefit from TDM-driven ad-
justments in ATV dosage with potential advantages in terms of costs and toxicity.
Introduction
Ritonavir-boosted atazanavir (ATV/r) is one of the two protease inhibitors (PI) selected as the
preferred choices in the American Department of Health and Human Services (DHHS) and
European guidelines for the initial treatment of patients infected with human immunodeficien-
cy virus-1 (HIV-1) [1,2]. This drug is relatively well tolerated in most patients; however, side ef-
fects including hyperbilirubinemia, which may result in visible jaundice or scleral icterus,
dyslipidemias, nephrolithiasis and cholelithiasis have been reported in the medium and long
term [3–6]. Ritonavir enhanced ATV concentrations and improved virologic activity more
than unboosted ATV [7]. Nevertheless, unboosted ATV may be selected for some patients be-
cause it has fewer gastrointestinal adverse effects, less hyperbilirubinemia and less impact on
lipid profiles than ATV/r.
Therapeutic drug monitoring (TDM) of ATV plasma trough concentrations is adopted for
the routine management of patients only in a minority of centres worldwide. However, consid-
erable inter-individual variability has been observed in plasma concentrations of ATV after
standard dosing, mainly related to drug-to-drug interactions and inherited differences in the
hepatic metabolism [8–12]. Significant correlations have been reported between plasma ATV
trough concentrations and clinical outcome. In treatment-experienced as well as naïve HIV pa-
tients the highest probability of achieving undetectable viral load has been associated with
ATV plasma concentrations>150 ng/mL [11–14]. Accordingly, this threshold concentration
is currently recommended by international guidelines for the optimal management of patients
on ATV-based antiretroviral regimens [15]. More scanty data are available concerning the rela-
tionships between ATV exposure and toxicity. A threshold ATV concentration of 800 ng/mL
has been proposed as a risk factor for hyperbilirubinemia [14,16,17], whereas no specific asso-
ciations have been reported for other ATV-related complications.
In the present study we sought to: I) assess the distribution of ATV plasma trough concen-
trations in HIV-infected patients according to drug dosage and II) verify a direct association
between ATV plasma concentration and the degree of hyperbilirubinemia. As an exploratory
analysis we also investigated the potential relationship between ATV concentrations and other
drug-related adverse events (nephrolithiasis and dyslipidemia).
Materials and Methods
Study population
Male and female HIV-infected patients on ATV-based antiretroviral therapy who underwent
TDM of ATV concentrations referring to the Department of Infectious Diseases at Luigi Sacco
University Hospital, Milan, Italy were enrolled in the present study. Paediatric subjects, pa-
tients with severe hepatic impairment (defined as Child-Pugh Class B or C) or with history of
kidney disease (including previous episodes of nephrolitiasis before initiation of ATV) were ex-
cluded from the present study. Written informed consent to patients management (that is
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consent for diagnostic evaluations, drug administration and all other medical procedures/inter-
ventions performed exclusively for routine treatment purposes) was collected to the first outpa-
tient visit. Patients provided also written informed consent for their records (anonymized) to
be used for future research purpose. In compliance with privacy laws, the patients’ identifica-
tion code was encrypted before performing the statistical analyses. Given the retrospective ob-
servational nature of the present investigation, no formal approval from the local ethics
committee was required according to the legislation of the national drug agency.
Adherence of patients to therapy was verified through direct questioning during every out-
patient visits. Data on self-reporting adherence were matched with data from our Pharmacy
Department in order to verify that patients have accepted the package with the antiretrovirals
dose required to fully cover the time between two visits. Only patients with high adherence to
antiretroviral medications (above 95% of the doses) were considered.
Study design
This study is based on a retrospective analysis of routine TDM of ATV carried out as day-by-
day clinical practice for the optimisation of drug dosing in HIV-infected patients between Jan-
uary 2010 and May 2013. HIV-infected patients treated with ATV for at least three months
and with one assessment of ATV plasma trough concentrations were included. ATV plasma
trough concentrations were stratified as below, within or above the therapeutic window, which
was set at 150–800 ng/mL according to the available literature [14,16,17].
Clinical information on ATV-related complications were recorded in each patient as fol-
lows. Hyperbilirubinaemia was scored from grade 0 to grade 4 in accordance with the AIDS
Clinical Trials Group Guidelines for total bilirubin levels [18]: grade 0 (<1.3 mg/dL); grade 1
(1.3–1.9 mg/dL); grade 2 (1.9–3.1 mg/dL); grade 3 (3.1–6.1 mg/dL); and grade 4 (>6.1 mg/dL).
Patients with the homozygous UGT1A128 genotype were excluded from the analysis (higher
risk to experience hyperbilirubinemia irrespective of ATV plasma concentrations). Dyslipide-
mia was defined by the concomitant presence of all these conditions: 1) total cholesterol>200
mg/dL or serum triglycerides >180 mg/dL; 2) at least a 20% increase in serum cholesterol or
serum triglyceride levels compared to baseline; 3) normal serum lipid levels at the last visit be-
fore starting ATV. Nephrolitiasis was defined as episode of acute flank pain plus one of the fol-
lowing: 1) new-onset hematuria confirmed by urine analysis, 2) documented presence of
stones or radiological findings suggestive of renal stones 3) stone passage confirmed by either
the patient or attending physician; in the absence of urinary oxalate or urate crystals and with
normal value of serum uric acid. Patients with history of nephrolitiasis before starting treat-
ment with ATV were not included in the present study.
Pharmacokinetic evaluations
Blood trough samples drawn into EDTA-containing vacutainers were collected from all pa-
tients immediately before the next drug intake, that is 24h or 12h after the last ATV adminis-
tration in patients given the drug qd or bid, respectively (a time window of ± 30 min was
directly verified by the nurse staff and considered as acceptable). All samples were centrifuged
at 3000 g (+4°C), then plasma was separated and stored at -20°C. Plasma ATV concentrations
were determined by a validated high-performance liquid chromatography (HPLC) method
coupled with tandem mass-spectrometric detection (LC-MS/MS), based on the assay originally
developed by Fayet et al [19]. Briefly, 100 microL of plasma sample was extracted by protein
precipitation with acetonitrile. After centrifugation an aliquot of the supernatant was analysed
by the LC-MS/MS system consisting in a Waters Alliance 2695 coupled with a Quattro Premier
XE triple quadrupole (Waters, Italy). Chromatographic separation was performed under
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gradient conditions on a reversed phase C18 column (Xbridge, 2.1X100 mm 3.5 microm parti-
cle sizes, Waters, Milan, Italy) maintained at 50°C. Mass-spectrometric analysis was performed
in positive electron spray ionisation mode. For quantification, multiple-reaction monitoring
(MRM) mode was applied to monitor the transitions from the precursor ion (M+H)+ to the
product ion (m/z 705.35 to m/z 335.3 for ATV). The method was linear over the ATV concen-
tration ranges of 20 to 9000 ng/mL. The lower limit of quantification of the method set at 20
ng/mL. Between and within-day imprecision and inaccuracy were less than 15%, as requested
by Consensus Guidelines on Bioanalytical Method Validations [20]. In addition our laboratory
participates in an external quality control programme for the continuous monitoring of the
method’s performance (the Dutch KKGT, available at http://www.kkgt.nl).
Statistical analyses
Results were given as mean (± standard deviation) or median (plus interquartile range) accord-
ing to distribution of the data based on results of the Kolmogorov-Smirnov normality test.
ATV plasma trough concentrations were stratified according to drug dosage (ATV dose, fre-
quency of daily drug administration and concomitant ritonavir use) and to therapeutic window
(set at 150–800 ng/mL). All comparisons between two groups were carried out using the un-
paired t test or Mann-Whitney test, whereas the ANOVA or Kruskall-Wallis tests were consid-
ered when comparing more than 2 groups, according to the distribution of the data.
The independent association between plasma ATV concentrations and dyslipidemia was as-
sessed by means of uni- and multi-variate regression analyses using the event (toxicity yes or
no) as dichotomic dependent variable and as independent covariates clinical, demographic and
pharmacologic data that resulted significantly associated with the event in the univariate models
(MEDCALC, Software). A p value of less than 0.05 was considered as statistically significant.
Results
Patients’ characteristics
Two-hundred forty HIV-infected adult patients were included in the present study. Demo-
graphic and clinical data of at the time of TDM are listed in Table 1. Patients were at 901 ± 870
days of therapy with ATV, mainly treated at the conventional ATV/r dosage 300/100 mg qd
(68%), given concomitantly with tenofovir-based antiretroviral regimens (56%). Ninety-two
percent of them were Caucasians. Thirty-nine (16%) out of the 240 patients evaluated (28 on
ATV 300/100 mg and 11 on ATV 400 mg) had detectable viral load at the time of TDM (medi-
an, interquartile range 2.36, 1.97–3.25 log cp/mL).
Distribution of ATV plasma trough concentrations
A wide distribution was observed in the ATV plasma trough concentrations, with median values
of 546 [204–1030] ng/mL, resulting in a mean inter-patient variability of 110.3%. Four percent
of the determinations resulted<20 ng/mL. As expected, mean ATV plasma concentrations
were higher in patients using ritonavir-boosted ATV than in patients using unboosted ATV
(given at 400 qd or 200 bid) (650 [357–1204] vs. 238 [99–551] ng/mL, p<0.0001).
As shown in Fig 1, a significant proportion of patients with ATV plasma trough concentra-
tions out of the therapeutic drug window were identified. 43.9% of patients treated with ATV
300/100 qd had ATV concentrations exceeding the upper therapeutic threshold, whereas
unboosted ATV 400 mg was associated with the highest proportion of values<150 ng/mL
(35.5%, Table 2).
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ATV plasma concentrations and hyperbilirubinemia
One-hundred forty-seven (61%) out of the 240 HIV-positive patients enrolled in the present
study experienced hyperbilirubinemia of grade1. As shown in Fig 2, a significant and direct
association has been observed between the severity of hyperbilirubinemia and ATV plasma
trough concentrations (ATV concentrations: 271 [77–555], 548 [206–902], 793 [440–1164],
768 [494–1527] and 1491 [1122–1798] ng/mL in patients with grade 0, 1, 2, 3 and 4 hyperbilir-
ubinemia, respectively, with p<0.01 of grade 2, 3, and 4 vs. grade 0). The same trend was con-
firmed also when repeating the above mentioned comparisons stratifying data according to
boosted or unboosted ATV intakers (Table 3).
ATV plasma concentrations and other drug-related adverse events
Overall, 55 out of the 240 HIV-positive patients developed dyslipidemia, namely hypercholester-
olemia (n = 26, mean increase 46±22%) or hypertriglyceridemia (n = 45, mean increase
114±76%). Patients with dyslipidemia had ATV concentrations significantly higher as compared
with patients with no ATV-related complications (582 [266–1148] vs. 218 [77–541] ng/mL,
p<0.01). This was confirmed also when repeating the above mentioned comparisons according
to ritonavir or not administration (Table 3). Moreover, in order to demonstrate a direct relation-
ship between ATV concentrations and lipid increase, we attempted to correlate ATV concentra-
tions with the magnitude of lipid levels increase as compared to baseline. Using this approach we
found a direct association between ATV concentrations and the percentage increase in serum
Table 1. Main demographic, hematologic and biochemical characteristics of HIV-positive patients receiving atazanavir as part of their antiretrovi-
ral regimen.
Parameters All Patients(n = 240) ATV/r 300/100 (n = 163) ATV 400 (n = 77)
Male gender, % 68% 74% 56%
Age, years 46±11 45±10 49±13
Naïve, % 23% 29% 11%
ATV therapy, days 901±870 846±886 1021±851
HAART, % 56% TDF-based 60% TDF-based 47% TDF-based
24% ABC-based 24% ABC-based 22% ABC-based
10% RAL-based 7% RAL-based 18% RAL-based
10% others 9% others 13% others
Weight, Kg 69±14 70±14 68±14
Body mass index, Kg/m2 24±4 24±4 24±4
Creatinine, mg/dL 0.9±0.4 0.9±0.3 0.9±0.7
GGT, IU/L 72±114 85±134 47±48
ALT, IU/L 47±49 49±53 42±40
Total bilirubin, mg/dL 2.1±1.6 2.3±1.7 1.7±1.2
Total cholesterol, mg/dL 187±46 191±48 178±39
HDL cholesterol, mg/dL 50±29 50±33 49±18
Triglycerides, mg/dL 167±124 179±132 143±104
CD4, cells/mL 593±247 572±249 639±239
Pts with VL>100 cp/mL, % 12% 13% 11%
HCV/HBV coinfection, % 34% 36% 26%
TDF: tenofovir; ABC: abacavir; RAL: raltegravir; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C virus; HBV: hepatitis
B virus; VL: viral load
doi:10.1371/journal.pone.0123670.t001
Atazanavir Concentrations and Drug-Related Adverse Events
PLOS ONE | DOI:10.1371/journal.pone.0123670 April 15, 2015 5 / 12
triglycerides levels (Fig 3). A similar, but not significant trend, was also observed for cholesterol
(data not shown).
At univariate analysis ATV concentrations (p<0.001), concomitant HAART (p = 0.079), ri-
tonavir use (p = 0.009) and patients’ gender (p = 0.046) were associated with the development
of dyslipidemia, while no association was found with other clinical covariates (Table 4). In the
multivariable regression analysis only ATV concentrations (p<0.01) and ritonavir use
(p = 0.02) remained independently associated with dyslipidemia.
Fig 1. Box-plot of atazanavir (ATV) plasma trough concentrations clustered according to drug
dosage.Dashed lines represent the upper and lower limits of the therapeutic window of ATV concentrations
(150–800 ng/mL).
doi:10.1371/journal.pone.0123670.g001
Table 2. Distribution of atazanavir (ATV) plasma trough concentrations according to daily drug dosage.
ATV, ng/mLmedian [IQR] Samples <150 ng/mL Samples150–800 ng/mL Samples >800 ng/mL
All evaluations (n = 240) 546 [204–1030] 21.2% 44.3% 34.4%
ATV/r 300/100 mg qd (n = 164) 650 [357–1204] 11.6% 44.5% 43.9%
ATV 400 mg* (n = 76) 238 [99–551] 35.5% 44.7% 19.8%
*given either as 400 mg qd or 200 mg bid; IQR: interquartile range
doi:10.1371/journal.pone.0123670.t002
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Eleven out of the 240 HIV-positive patients enrolled in the present study experienced epi-
sodes of nephrolitiasis indirectly attributed to ATV after having excluded other clinical condi-
tions predisposing to kidney stones. As shown in Table 3 these patients were mainly treated
with ritonavir (82%) and had ATV concentrations significantly higher as compared with
Fig 2. Box plot of ATV plasma trough concentrations clustered according to the grade of
hyperbilirubinemia (scored as grade 0, 1, 2, 3 or 4 based on total bilirubin concentrations below 1.3
mg/dL, between 1.3–1.9, 1.9–3.1, 3.1–6.1, or above 6.1 mg/dL, respectively). *p<0.01 vs grade 0.
doi:10.1371/journal.pone.0123670.g002
Table 3. Atazanavir (ATV) plasma trough concentrations measured in patients that did or did not experienced drug-related adverse events.
Adverse event n Overall patients n ATV/r 300/100 n ATV 400
Hyperbilirubinemia
- Grade 0 86 271 (77–555) 52 347 (121–785) 34 141 (56–293)
- Grade 1 45 548 (206–902) 30 634 (355–962) 15 194 (106–358)
- Grade 2 54 793 (440–1164)* 40 909 (586–1264)** 14 466 (260–804)**
- Grade 3 41 768 (494–1527)* 31 825 (531–1368)** 10 540 (394–1979)*
- Grade 4 7 1491 (1122–1798)* 6 1363 (1066–1693)** 1 1836
Dyslipidemia 55 582 (266–1148)* 44 746 (305–1313)** 11 250 (106–486)
Nephrolitiasis 11 1098 (631–1238)* 9 1098 (652–1285)** 2 742 (293–1191)
Controls^ 66 218 (77–541) 39 343 (125–810) 27 141 (50–259)
Data were stratiﬁed also according to ritonavir use.
^patients that did not develop ATV-related adverse events;
*p<0.01 and
**p<0.05 vs. controls
doi:10.1371/journal.pone.0123670.t003
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Fig 3. Box plot of ATV plasma trough concentrations clustered according to the magnitude of
triglyceride concentrations increase as compared to valuesmeasured at the last visit before starting
ATV. *p<0.01 and **p<0.05 vs. patients experiencing20% increase (first column from the left).
doi:10.1371/journal.pone.0123670.g003
Table 4. Univariate andmultivariate regression analysis of clinical, demographic and pharmacological covariates associated with the develop-
ment of atazanavir (ATV)-related dyslipidemia.
Univariate Multivariate
Variable r-value p-value r- value p-value
Gender 0.14 0.046
Age 0.04 0.502
Body weight 0.04 0.469
Serum creatinine 0.01 0.616
ALT <0.01 0.276
GGT 0.01 0.172
HCV/HBV Coinfection 0.01 0.873
CD4 count 0.02 0.336
Concomitant ARV drugs 0.12 0.079
Days of ATV therapy <0.01 0.980
ATV concentrations 0.35 <0.001 0.33 <0.01
Ritonavir use 0.18 0.009 0.18 0.02
r-value: correlation coefﬁcient; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C virus; HBV: hepatitis B virus;
ATV: atazanavir
doi:10.1371/journal.pone.0123670.t004
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patients with no ATV-related complications (1098 [631–1238 vs. 218 [77–541] ng/mL,
p<0.01). Only one out of 240 patients experienced an episode of cholelithiasis 226 days after
starting treatment with ATV (ATV plasma trough concentrations: 438 ng/mL).
Discussion and Conclusion
In this study, we document that a significant proportion of HIV-infected patients treated with
ATV at the standard 300/100 mg qd dosage had plasma drug concentrations largely exceeding
the upper therapeutic threshold, whereas nearly one third of patients treated with unboosted
ATV had drug concentrations below 150 ng/mL, considered as the minimum concentration to
be reached for the optimal management of patients on ATV-based antiretroviral regimens [15].
More than 60% of HIV-positive patients enrolled in the present study experienced hyperbi-
lirubinemia of grade 1 or more, allowing us to deeply investigate the potential contribution of
ATV concentrations on this drug-related adverse event. In our study we firstly confirmed the
previously reported relationship between ATV exposure and the increase in total bilirubin con-
centrations [14,16,17]. Moreover, we extended previous findings by documenting a direct and
linear correlation between ATV trough concentrations and the severity of hyperbilirubinemia.
Interestingly, such relationship was established also when excluding patients homozygous for
the UGT1A128, the genotype associated with a defect in the metabolism of bilirubin [21,22].
Using this approach, we demonstrated that association of ATV exposure with hyperbilirubine-
mia still persisted also in patients with the favourable UGT genotype. Accordingly, it could be
speculated that in these patients, lacking of an inherited risk to experience the event, ATV-
related hyperbilirubinemia might be eventually reversed by reducing ATV doses.
The potential effect of ATV on lipid profile is still a matter of debate. Meta-analyses have re-
ported that plasma lipid concentrations were lower with ATV/r than with other ritonavir-
boosted PI regimens [23]. Nevertheless, evidence is also available showing that ATV has a
worst atherogenic lipid profile compared with non nucleoside reverse transcriptase inhibitors
[6]. Our exploratory analyses study extended previous findings by documenting that also dysli-
pidemia might be associated with ATV plasma trough concentrations. In order to demonstrate
a direct relationship between ATV exposure and lipid increase, we correlated ATV concentra-
tions with the magnitude of lipid levels increase as compared to baseline. Using this approach
we found a linear and significant association between ATV concentrations and the percentage
increase in serum triglycerides levels, but not for cholesterol, probably because of the less num-
ber of events and the narrow distribution in the percentage increased compared with triglycer-
ide concentrations. Among the different ATV-based regimens, lipid alterations were more
frequently found in patients on ATV/r that in those given ATV alone [7], suggesting a key
role of ritonavir [24]. This has been fairly confirmed also by our study by documenting that:
I) patients experiencing ATV-related complications were more frequently receiving ritonavir;
II) the significant association between ritonavir and ATV-related dyslipidemia was confirmed by
multivariate analyses. In order to avoid the potential bias related to ritonavir use associated to
the fact that a higher proportion of patients in the “adverse effect group” were treated with
boosted ATV compared with control patients (those who did not experienced ATV-related com-
plications), we repeated our comparisons stratifying data according to ritonavir boosted/
unboosted intakers. Also using this approach, we documented that among patients given ATV/r
300/100, those experiencing dyslipidemia have significantly higher ATV concentrations com-
pared with those not experiencing drug-related complications. A similar, but not significant,
trend was found also in patients treated with ATV 400 mg. The small number of ATV unboosted
intakers did not allow us to reach definitive conclusion on this topic. We are, however, confident
that our preliminary findings could provide the rationale for ad-hoc prospective studies aimed at
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investigating the impact of ATV exposure on dyslipidemia in unboosted regimens. We also ac-
knowledged that, as an important additional limitation, no information were available on ritona-
vir exposure, because ritonavir concentrations are not assessed in the routine management of
HIV patients. Accordingly, the potential contribution of ritonavir co-administration on episodes
of dyslipidemia in patients treated with ATV cannot be completely ruled out.
Cases of complicated and uncomplicated ATV-associated nephrolithiasis have been de-
scribed, sometimes leading to obstructive uropathy and acute renal failure [25–28]. The associ-
ation between exposure to ATV and increased incidence kidney stones has been subsequently
confirmed also by epidemiological studies [5,29]. To the best of our knowledge, our is the first
report showing that overexposure to ATV is associated also with increased risk of nephrolitia-
sis. It should be, however, acknowledged that as potential limitation of the present observation,
the presence of ATV in the stones was not directly verified, and that episodes of drug-related
nephrolitiasis were diagnosed indirectly after excluding the presence of oxalate or urate crystals
in urinalysis and high value of serum uric acid.
The potential association between exposure to ATV and increased risk to cholelithiasis is
still a matter of debate. Indeed, Hamada and co-workers reported a low incidence of complicat-
ed cholelitiasis in patients on ATV comparable to other PIs [30]. These results have been par-
tially challenged by recent findings from the same authors [31] reporting an increased risk of
cholelithiasis in patients treated with ATV for more than two years. In our cohort, we found
only one episode of cholelithiasis in a patient treated with ATV for less than one year.
In conclusion, in this study we documented that significant proportion of patients treated
with conventional ATV dosages had plasma concentrations exceeding the upper therapeutic
threshold. A likely possibility is an inherited deficit in ATV clearance [32] and/or ATV metab-
olism; in particular, ATV is a dedicated CYP3A substrate, which includes 3A4 and 3A5, two
polymorphic genes [8,9,10]. The administration of unboosted ATV to healthy subjects carrying
the defective CYP3A53 resulted in significantly higher ATV concentrations compared with
values measured in patients expressing CYP3A5 [21]. Assuming that over 90% of patients in
our study were Caucasians with a high prevalence of carriers of CYP3A5 3, it is likely that the
observed overexposure to ATV concentrations is the result of excessively high dose of ritona-
vir-boosted ATV or of needless boosting with ritonavir. This is a first important conclusion of
our study that raises concerns on the need of full dose of ritonavir-boosted ATV in Caucasian
patients and opens new questions about the ATV dosages that should considered correct (or in
label and off label in Europe). This may be particularly relevant in light of the recent findings
showing that ritonavir may accumulate at intracellular level at higher degree than other PIs
providing additional antiviral activity and eventually allowing the use of reduced PI doses [33].
We also found that such patients have the highest risk of experiencing ATV-related complica-
tions and may benefit from TDM-driven adjustments in ATV dosage with potential advantages
in terms of costs and toxicity.
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